|Melanoma Diagnostics Leader, MELA Sciences, Inc., Participates in Skin Cancer ...|
MELA Sciences, Inc. (NASDAQ:MELA), designer and developer of MelaFind(R) , an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin ...
Wall Street Journal - Fri, 06 Dec 2013 04:56
|Scientists ID Better Approach to Analyze Melanoma's Genetic Causes|
There may be a better way to analyze the genetic causes of cutaneous melanoma (CM) according to a study published in Human Genetics conducted by researchers Yale and Dartmouth. A statistical analysis using the natural and orthogonal interaction ...
Bioscience Technology - Wed, 11 Dec 2013 19:11
|KSC junior advocates for sun protection after treatment for melanoma saves his ...|
Melanoma is one of the most common cancers found in people who are under 30-years-old, although according to cancer.org it is most commonly found in older adults and men are more likely to have it. DeLuke was told by his doctor that if he had not gone ...
keene-equinox - Thu, 12 Dec 2013 11:07
|Stage III/IV melanoma patients at risk for NPMs|
(HealthDay News) -- Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower than those observed in studies of ...
Oncology Nurse Advisor - Tue, 10 Dec 2013 04:11
|Stage III/IV Melanoma Patients at Risk for New Primaries|
(HealthDay News) – Patients with Stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower than those observed in studies of ...
Monthly Prescribing Reference - Tue, 10 Dec 2013 06:09
|Melanoma Diagnostics Leader, MELA Sciences, Hosts Clinical Advisory Meeting ...|
NEW YORK & IRVINGTON, N.Y., Dec 05, 2013 (BUSINESS WIRE) -- MELA Sciences, Inc. (NASDAQ:MELA) designer and developer of MelaFind(R), an FDA approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most ...
MarketWatch - Thu, 05 Dec 2013 04:57
|Melanoma pill approved for use in Scotland|
The decision was based on data showing vemurafenib can extend life to an average of more than 13 months for patients with metastatic melanoma compared to less than 10 months for those given chemotherapy. The data also showed it could stop the skin ...
Nursing Times - Tue, 10 Dec 2013 02:46
|Cancer drug approved for NHS use|
Kirriemuir Herald - Mon, 09 Dec 2013 08:07
|Scots back new cancer drug move|
Glasgow Evening Times - Mon, 09 Dec 2013 22:56
|T-VEC Shows Efficacy in Melanoma Trial|
Chicago—In a Phase III trial of stage IIIB-IV melanoma patients, a vaccine engineered from herpes simplex virus improved durable response rate compared with granulocyte macrophage colony-stimulating growth factor (GM-CSF). The trial of talimogene ...
Clinical Oncology News - Wed, 11 Dec 2013 11:07